Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer

Sara M. Johnson, Pat Gulhati, Bill A. Rampy, Yimei Han, Piotr G. Rychahou, Hung Q. Doan, Heidi L. Weiss, B. Mark Evers

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Background: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway plays a critical role in the growth and progression of colorectal cancer (CRC). The purpose of our study was 2-fold: (1) to determine the expression levels of several key components of this pathway, including p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 in CRCs; and (2) to correlate the expression of these proteins with cancer stage and location (left versus right side). Study Design: Immunohistochemistry for p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 was performed on normal colon and CRCs from 154 patients. Results: All proteins investigated were significantly overexpressed in CRCs compared with matched normal colonic tissue from the same patient (p < 0.0001). PI3K pathway component proteins were moderately correlated across normal and malignant colon tissues; correlations tended to be stronger in normal tissues as compared with the same correlations in cancers. Expression levels of p85α were significantly higher in stage IV cancers than in stage I to III cancers (p = 0.0005). p85α expression was also significantly increased in the adjacent normal colonic mucosa of patients with stage IV CRC compared with earlier stages (p = 0.003). Finally, expression of Akt1, Akt2, and p-p70S6KThr389 was higher in left-sided CRCs compared with CRCs in the right colon (p = 0.007, p = 0.0008, and p = 0.04, respectively). Conclusions: The PI3K/Akt/mTOR pathway components, p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 are highly overexpressed in CRCs, providing the rationale for targeting this pathway therapeutically in CRC patients. The increased expression of p85α in the adjacent normal mucosa of stage IV patients suggests an important field defect, which may contribute to the growth and progression of these cancers.

Original languageEnglish (US)
Pages (from-to)767-776
Number of pages10
JournalJournal of the American College of Surgeons
Volume210
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Phosphatidylinositol 3-Kinase
Sirolimus
Colorectal Neoplasms
Colon
Neoplasms
Mucous Membrane
Proteins
Growth
Phosphatidylinositol 3-Kinases
Immunohistochemistry

ASJC Scopus subject areas

  • Surgery

Cite this

Johnson, S. M., Gulhati, P., Rampy, B. A., Han, Y., Rychahou, P. G., Doan, H. Q., ... Evers, B. M. (2010). Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer. Journal of the American College of Surgeons, 210(5), 767-776. https://doi.org/10.1016/j.jamcollsurg.2009.12.008

Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer. / Johnson, Sara M.; Gulhati, Pat; Rampy, Bill A.; Han, Yimei; Rychahou, Piotr G.; Doan, Hung Q.; Weiss, Heidi L.; Evers, B. Mark.

In: Journal of the American College of Surgeons, Vol. 210, No. 5, 05.2010, p. 767-776.

Research output: Contribution to journalArticle

Johnson, SM, Gulhati, P, Rampy, BA, Han, Y, Rychahou, PG, Doan, HQ, Weiss, HL & Evers, BM 2010, 'Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer', Journal of the American College of Surgeons, vol. 210, no. 5, pp. 767-776. https://doi.org/10.1016/j.jamcollsurg.2009.12.008
Johnson, Sara M. ; Gulhati, Pat ; Rampy, Bill A. ; Han, Yimei ; Rychahou, Piotr G. ; Doan, Hung Q. ; Weiss, Heidi L. ; Evers, B. Mark. / Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer. In: Journal of the American College of Surgeons. 2010 ; Vol. 210, No. 5. pp. 767-776.
@article{ae1c7c00191f452cab765888267551e0,
title = "Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer",
abstract = "Background: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway plays a critical role in the growth and progression of colorectal cancer (CRC). The purpose of our study was 2-fold: (1) to determine the expression levels of several key components of this pathway, including p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 in CRCs; and (2) to correlate the expression of these proteins with cancer stage and location (left versus right side). Study Design: Immunohistochemistry for p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 was performed on normal colon and CRCs from 154 patients. Results: All proteins investigated were significantly overexpressed in CRCs compared with matched normal colonic tissue from the same patient (p < 0.0001). PI3K pathway component proteins were moderately correlated across normal and malignant colon tissues; correlations tended to be stronger in normal tissues as compared with the same correlations in cancers. Expression levels of p85α were significantly higher in stage IV cancers than in stage I to III cancers (p = 0.0005). p85α expression was also significantly increased in the adjacent normal colonic mucosa of patients with stage IV CRC compared with earlier stages (p = 0.003). Finally, expression of Akt1, Akt2, and p-p70S6KThr389 was higher in left-sided CRCs compared with CRCs in the right colon (p = 0.007, p = 0.0008, and p = 0.04, respectively). Conclusions: The PI3K/Akt/mTOR pathway components, p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 are highly overexpressed in CRCs, providing the rationale for targeting this pathway therapeutically in CRC patients. The increased expression of p85α in the adjacent normal mucosa of stage IV patients suggests an important field defect, which may contribute to the growth and progression of these cancers.",
author = "Johnson, {Sara M.} and Pat Gulhati and Rampy, {Bill A.} and Yimei Han and Rychahou, {Piotr G.} and Doan, {Hung Q.} and Weiss, {Heidi L.} and Evers, {B. Mark}",
year = "2010",
month = "5",
doi = "10.1016/j.jamcollsurg.2009.12.008",
language = "English (US)",
volume = "210",
pages = "767--776",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer

AU - Johnson, Sara M.

AU - Gulhati, Pat

AU - Rampy, Bill A.

AU - Han, Yimei

AU - Rychahou, Piotr G.

AU - Doan, Hung Q.

AU - Weiss, Heidi L.

AU - Evers, B. Mark

PY - 2010/5

Y1 - 2010/5

N2 - Background: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway plays a critical role in the growth and progression of colorectal cancer (CRC). The purpose of our study was 2-fold: (1) to determine the expression levels of several key components of this pathway, including p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 in CRCs; and (2) to correlate the expression of these proteins with cancer stage and location (left versus right side). Study Design: Immunohistochemistry for p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 was performed on normal colon and CRCs from 154 patients. Results: All proteins investigated were significantly overexpressed in CRCs compared with matched normal colonic tissue from the same patient (p < 0.0001). PI3K pathway component proteins were moderately correlated across normal and malignant colon tissues; correlations tended to be stronger in normal tissues as compared with the same correlations in cancers. Expression levels of p85α were significantly higher in stage IV cancers than in stage I to III cancers (p = 0.0005). p85α expression was also significantly increased in the adjacent normal colonic mucosa of patients with stage IV CRC compared with earlier stages (p = 0.003). Finally, expression of Akt1, Akt2, and p-p70S6KThr389 was higher in left-sided CRCs compared with CRCs in the right colon (p = 0.007, p = 0.0008, and p = 0.04, respectively). Conclusions: The PI3K/Akt/mTOR pathway components, p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 are highly overexpressed in CRCs, providing the rationale for targeting this pathway therapeutically in CRC patients. The increased expression of p85α in the adjacent normal mucosa of stage IV patients suggests an important field defect, which may contribute to the growth and progression of these cancers.

AB - Background: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway plays a critical role in the growth and progression of colorectal cancer (CRC). The purpose of our study was 2-fold: (1) to determine the expression levels of several key components of this pathway, including p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 in CRCs; and (2) to correlate the expression of these proteins with cancer stage and location (left versus right side). Study Design: Immunohistochemistry for p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 was performed on normal colon and CRCs from 154 patients. Results: All proteins investigated were significantly overexpressed in CRCs compared with matched normal colonic tissue from the same patient (p < 0.0001). PI3K pathway component proteins were moderately correlated across normal and malignant colon tissues; correlations tended to be stronger in normal tissues as compared with the same correlations in cancers. Expression levels of p85α were significantly higher in stage IV cancers than in stage I to III cancers (p = 0.0005). p85α expression was also significantly increased in the adjacent normal colonic mucosa of patients with stage IV CRC compared with earlier stages (p = 0.003). Finally, expression of Akt1, Akt2, and p-p70S6KThr389 was higher in left-sided CRCs compared with CRCs in the right colon (p = 0.007, p = 0.0008, and p = 0.04, respectively). Conclusions: The PI3K/Akt/mTOR pathway components, p85α, Akt1, Akt2, p-mTORSer2448, and p-p70S6KThr389 are highly overexpressed in CRCs, providing the rationale for targeting this pathway therapeutically in CRC patients. The increased expression of p85α in the adjacent normal mucosa of stage IV patients suggests an important field defect, which may contribute to the growth and progression of these cancers.

UR - http://www.scopus.com/inward/record.url?scp=77952311165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952311165&partnerID=8YFLogxK

U2 - 10.1016/j.jamcollsurg.2009.12.008

DO - 10.1016/j.jamcollsurg.2009.12.008

M3 - Article

C2 - 20421047

AN - SCOPUS:77952311165

VL - 210

SP - 767

EP - 776

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 5

ER -